Eleuthero (Siberian Ginseng)

Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. belongs to Araliaceae, the ginseng and ivy family. Kew’s Plants of the World Online accepts the name, first published in 1859, and gives the native range as the Russian Far East to central China and Japan, taking in Amur, Khabarovsk, Primorye, Sakhalin, Manchuria, Inner Mongolia, Korea, and north-central and south-central China; it is a shrub of the temperate biome. EMA notes that it was long known as Acanthopanax senticosus, a name Chinese scientists still widely use. Patyra and colleagues (Frontiers in Pharmacology 2025) explain the names: Eleutherococcus comes from the Greek eleutheros, free, and kokkos, a seed or stone; senticosus is Latin for full of briers or thorns; and Acanthopanax means thorny ginseng. The genus has almost 40 species. Russians call the plant eleutherokokk, and the name Siberian ginseng was introduced in the United States because the root was first exported from Siberia in the Soviet era. EMA records German and Hungarian names meaning taiga root, and Danish, Swedish, and Norwegian names meaning Russian root.

It is a shrub usually 2 to 7 m tall, with several mostly unbranched stems whose branches carry dense or scattered prickles about 5 mm long (Patyra). The leaves are palmately compound, with three to five elliptic to oblong leaflets on thorny stalks; Flora of China describes the leaflets as usually five, 5–13 cm long, with sharply double-toothed margins. Small purple-yellow flowers are borne in rounded umbels at the tips of leafy shoots, singly or in groups, in June and July, and ripen from August to October into black, berry-like drupes about 8–10 mm across. Patyra notes that the flowers and fruits resemble those of ivy, another member of the family. Flora of China records the plant in thickets, forests, roadsides, and valleys below 2,000 m. The medicinal part is the root and rhizome: the European Pharmacopoeia defines the drug as the dried, whole or cut underground organs, containing at least 0.08% of eleutherosides B and E combined (EMA). The leaves have also been studied, but the trials discussed here used root extracts.

Eleuthero’s chemistry is unlike ginseng’s. EMA counts more than 35 identified compounds and notes that the search for the active ones is not finished. The eleutherosides are a mixed group named by letter rather than by chemical family. Eleutheroside B is syringin, a phenylpropanoid making up about 0.5% of the root; eleutheroside E is a lignan, a syringaresinol diglucoside, at about 0.1%; eleutheroside B1 is a glucoside of the coumarin isofraxidin; and eleutherosides A and K are grouped with the triterpene saponins. The root also contains chlorogenic acid (up to 0.3%), the lignan sesamin, polysaccharides called eleutherans, and about 0.8% essential oil (EMA). Eleutherosides B and E are used to standardize products, and Patyra notes that syringin is a particularly specific marker for telling eleuthero apart from other plants in the family, which matters because substitution with related species is a recurring problem. LactMed, the US government database on medicines in breastfeeding, stresses that eleuthero has different constituents from true ginseng.

In China the plant is ci wu jia. Patyra and colleagues trace its first description to the Shennong Bencao Jing, a classic of Chinese herbal medicine variously dated to between 100 BC and AD 200 or much earlier, and note that it is listed in the modern Chinese Pharmacopoeia. In traditional Chinese medical theory, ci wu jia nourishes qi, the body’s vital energy, fortifies the spleen, strengthens the bones, and calms the mind. EMA’s assessment report, citing earlier surveys, says the plant was used as a folk remedy in the north-eastern Chinese city of Harbin for bronchitis, heart ailments, and rheumatism, and that regular use was thought to restore vigor, improve general health, restore memory, promote a good appetite, and increase longevity, serving as a general tonic and preventive medicine. It has also been a folk medicine for hepatitis and cancer in Taiwan. These traditions are long-standing, but they come from a medical system with different ideas about disease, and none of these uses has been confirmed in modern trials.

Eleuthero’s fame outside Asia came through Soviet science. Patyra and colleagues relate that a physician, P. E. Kirilov, brought the plant from Beijing to Russia in 1842 and that C. I. Maximowicz later described it botanically. In the late 1940s Soviet researchers began looking for substances that would raise the body’s nonspecific resistance to stress, and in 1958 the term adaptogen was introduced; EMA attributes it to Soviet scientists describing eleuthero’s actions, and Patyra credits the toxicologist N. V. Lazarev. Because wild Panax ginseng was scarce, Soviet researchers looked for a substitute with similar activity and settled on eleuthero (Patyra), and I. I. Brekhman became its leading investigator. EMA’s assessment report dates Brekhman’s first article on the plant to 1960 and records that the Soviet Pharmacological Committee approved an eleuthero root extract for clinical use as a stimulant in 1962, that the root was recommended for the Soviet space program in 1966, and that Brekhman published the first book on it, Eleutherococcus, in 1968. More than 1,000 articles followed. Brekhman reported giving the extract to more than 1,500 sportsmen; in one series in 1961 and 1962, 30 Olympic athletes taking it were said to recover faster and show better endurance than a placebo group.

The Soviet evidence was large in volume but weak in design. EMA describes 35 uncontrolled trials in more than 2,100 healthy people and another 35 in about 2,200 patients with conditions from atherosclerosis to chronic bronchitis, reporting better work performance and fewer illnesses without statistical evaluation or control groups; other reports described eleuthero helping sailors on tropical voyages and people adapting to high altitude and the Arctic. Brekhman and Dardymov’s 1969 review in the Annual Review of Pharmacology set out the criteria that still define an adaptogen: it should be harmless, act nonspecifically to raise resistance to many kinds of stress, and normalize body functions whichever way they have been disturbed (Patyra). In the West, EMA notes, eleuthero was the first English name, created in the United States, and Siberian ginseng was used there from 1971 until the 2002 Farm Bill added a provision to federal food law making it misbranding to sell a product as ginseng unless it comes from Panax. In Europe, powdered root medicines were on the German market before 1978; EMA’s herbal committee adopted its monograph in 2008, revised it in 2014, and opened a periodic review in 2025.

No one has pinned down how eleuthero might work, partly because the adaptogen idea itself is so broad. EMA’s assessment report observes that the concept is not well known to Western medicine and is absent from standard textbooks such as Goodman and Gilman’s pharmacology and Harrison’s internal medicine, and that many eleuthero studies set out to prove the concept rather than to treat a defined disease. Supporters propose that adaptogens act on the body’s stress system, the hypothalamic-pituitary-adrenal axis, and on stress-response molecules such as the heat shock protein Hsp70, cortisol, and nitric oxide; Panossian and Wikman (Current Clinical Pharmacology 2009), writing from the Swedish Herbal Institute, argue that raising Hsp70 is the key action. EMA summarizes a mouse study in which a combination of eleuthero, schisandra, and rhodiola extracts raised blood levels of Hsp72 and greatly lengthened swimming time before exhaustion. These are hypotheses built on laboratory and animal data, not explanations of a proven effect in people.

Laboratory studies point in many directions at once. MSKCC summarizes work in which eleuthero extracts damped inflammatory signaling in immune cells, eleutherosides B and E and isofraxidin protected cultured rat nerve cells from damage, eleutherosides eased physical and mental fatigue in mice, and syringin lowered blood sugar in diabetic rats; EMA adds that eleutheroside E improved insulin sensitivity in obese diabetic mice. In the test tube, eleuthero constituents bound to estrogen, progestin, mineralocorticoid, and glucocorticoid receptors (MSKCC), though not, EMA notes, to the androgen receptor. Patyra and colleagues conclude that eleuthero’s adaptogenic action, as seen in mostly simplified laboratory models, combines anti-inflammatory, immune-modulating, antioxidant, and nerve-protective effects. Sources disagree on blood sugar: animal studies suggest a lowering effect, while LactMed lists raised blood sugar among possible effects in people. None of this shows what an eleuthero capsule does in a tired person.

How much reaches the bloodstream is another open question. In rats, Ma and colleagues, summarized by EMA, found that eleutherosides B and E were absorbed quickly, peaking within about half an hour, but that only about 3% to 4% of an oral dose reached the circulation, with half-lives under 2.5 hours; both reached higher levels when given as a whole water extract than as pure compounds. In healthy volunteers, a standardized eleuthero extract did not affect CYP2D6 or CYP3A4, two liver enzymes that clear many drugs, but in cell studies it suppressed P-glycoprotein, a pump that moves digoxin and other medicines across the gut wall (EMA). EMA judged the clinical data inconclusive but found the traditional use plausible on the basis of long-standing use and the many pharmacological and clinical studies, while noting that the data justify further research into the adaptogen concept itself.

Fatigue and weakness: this is eleuthero’s main use and the one EMA accepts as traditional. The best-known trial is by Hartz and colleagues (Psychological Medicine 2004), who randomized 96 adults with at least six months of substantial, unexplained fatigue, most recruited through advertisements in Iowa and some from chronic fatigue syndrome support groups, to a standardized root extract or placebo for two months; EMA records that the extract supplied 2.24 mg of eleutherosides B and E a day. Seventy-six people completed the two-month follow-up. Fatigue fell substantially in both groups, but the difference between them was not statistically significant. In subgroup analyses, eleuthero seemed to help the 45 people with less severe fatigue (P = 0.04, not adjusted for multiple comparisons) and, less clearly, the 41 who had been tired for five years or more. The authors concluded that overall efficacy was not demonstrated, but that the finding in moderate fatigue might justify further research. Unadjusted subgroup results like these are a reason for a new trial, not a conclusion.

Stress-related exhaustion and well-being: Schaffler and colleagues (Pharmacopsychiatry 2013) randomized 144 adults with asthenia and reduced working capacity related to chronic stress to 120 mg a day of a dry root extract, a two-day stress management course, or both, for eight weeks. Nearly every measure, from fatigue and mood to sleep and cognitive tests, improved over time in all three groups without differences between them, and the authors concluded that the effect of adding eleuthero to stress management training was, if anything, negligible. The trial was open rather than blinded and had no placebo arm. In a small double-blind trial by Cicero and colleagues (Archives of Gerontology and Geriatrics 2004), 20 people aged 65 or over with high blood pressure who were taking digoxin received 300 mg of eleuthero extract a day or placebo for eight weeks. Social functioning scores were better with eleuthero at four weeks, but the difference had faded by eight, and 70% of those on eleuthero said they thought they were on active treatment, against 20% of those on placebo.

Athletic performance: Soviet reports of better endurance in Olympic athletes made eleuthero popular in sport, but controlled studies have not borne this out. Dowling and colleagues (Medicine and Science in Sports and Exercise 1996) gave 20 highly trained distance runners 3.4 ml of eleuthero extract or placebo daily for six weeks, testing them repeatedly at 10 km race pace and on maximal treadmill runs; there were no differences in heart rate, oxygen use, breathing, blood lactate, perceived effort, or time to exhaustion. Goulet and Dionne (International Journal of Sport Nutrition and Exercise Metabolism 2005) reviewed the endurance studies: three that reported substantial benefits had severe methodological flaws, while five rigorous studies found no benefit, and they concluded that eleuthero at up to 1,000 to 1,200 mg a day for one to six weeks offers no advantage in exercise lasting 6 to 120 minutes. A later crossover trial by Kuo and colleagues (Chinese Journal of Physiology 2010) reported 23% longer cycling time after eight weeks of 800 mg a day, but in only nine men, too few, EMA judged, to show efficacy.

Colds and immunity: eleuthero is widely sold to prevent colds, but the encouraging trials tested a combination. Kan Jang, which pairs a standardized extract of andrographis (Andrographis paniculata) with eleuthero, reduced cold symptoms more than placebo in a 179-patient trial by Melchior and colleagues (Phytomedicine 2000) and in a 185-patient trial in colds and sinusitis by Gabrielian and colleagues (Phytomedicine 2002). Poolsup and colleagues (Journal of Clinical Pharmacy and Therapeutics 2004) pooled three trials with 433 patients and found the combination improved symptom severity scores by about 2 points more than placebo; they also found andrographis alone more effective than placebo. Each Kan Jang tablet contains eleuthero extract corresponding to only 120 mg of dried root (EMA), so these trials say little about eleuthero itself. In a Soviet controlled study of 1,376 people during an influenza epidemic, illness rates were lower with 2 ml of eleuthero extract daily but not significantly so, although complications such as bronchitis and pneumonia were less frequent (EMA).

Other uses: EMA’s assessment report, citing the European Scientific Cooperative on Phytotherapy (ESCOP), describes a six-month double-blind trial by Williams (1995) in 93 people with recurrent genital herpes (herpes simplex type 2), in which 75% of those taking 400 mg of eleuthero extract daily reported fewer, milder, or shorter outbreaks, against 34% on placebo; the results came from questionnaires comparing the six months before and after treatment. A Cochrane review by Li and colleagues (2009) found 13 Chinese trials of acanthopanax in 962 people with acute ischemic stroke; more people improved neurologically, but every trial was at high risk of bias, and the reviewers said the data were not adequate to draw reliable conclusions. MSKCC notes small studies of an herbal mixture containing eleuthero for knee osteoarthritis and of blood lipids in postmenopausal women. None of these findings makes eleuthero a treatment for herpes, stroke, arthritis, or cholesterol.

EMA’s monograph lists the forms and daily doses accepted for traditional use in adults, the elderly, and adolescents over 12: 0.5–4 g of cut root as a tea, infused in 150 ml of boiling water; 0.75–3 g of powdered root; 2–3 ml of a 1:1 liquid extract; dry alcoholic extracts equivalent to 0.5–4 g of root; 90–180 mg of a dry water extract; 10–15 ml of a 1:5 tincture in 40% alcohol; or one of two extracts made with sweet wine. The daily amount can be split into one to three doses. A course should not last more than two months, and anyone whose symptoms persist beyond two weeks of use, or get worse, should see a doctor. EMA explains the two-week rule: traditional medicines must be usable without medical supervision, and persistent symptoms may signal a disease that needs diagnosis. Older handbooks cited by EMA, including the WHO monograph and the British Herbal Compendium, give 2–3 g of root a day, and traditional regimens used courses of 25 to 30 days repeated after breaks of one to two weeks.

Clinical trials used a mixture of products: a standardized extract providing 2.24 mg of eleutherosides B and E daily in the chronic fatigue trial (taken as four 500 mg capsules, according to Patyra), 120 mg of dry extract in the stress trial, 300 mg in the elderly trial, 3.4 ml of an alcoholic extract in the runner study, and 800 mg in the small cycling trial. Soviet studies mostly used a 33% alcohol root extract at 2 to 20 ml a day for up to 60 days. Because these products differ in strength and standardization, results from one cannot be transferred to another, and a capsule labeled only “Siberian ginseng” may not resemble any of them. Combination products such as Kan Jang, and the many energy and immune blends that include eleuthero, contain other active herbs, and EMA’s assessment covered eleuthero root alone.

Quality is a real concern. When Harkey and colleagues (American Journal of Clinical Nutrition 2001) analyzed 25 ginseng-type products from a US health food store, every product contained the plant genus it claimed, but marker compound levels often differed from the labels, and eleutheroside concentrations varied 43-fold between capsules and 200-fold between liquid products. Patyra and colleagues add that substitution with other members of the ginseng family and mismatches with the declared eleutheroside content are recurring problems, and the two best-known eleuthero safety scares involved products suspected of containing silk vine. Choose a product that names Eleutherococcus senticosus root and states its eleutheroside B and E content, ideally a registered traditional herbal medicine or a product verified by an independent testing organization. EMA notes that eleuthero may cause insomnia if taken too close to bedtime, so take it in the morning or early afternoon, and remember that tinctures and liquid extracts contain alcohol.